文献速递老年慢病共病管理多重用药

美国养老院居民磺脲类药物比较安全性研究

Comparative safety of sulfonylureas among U.S. nursing home residents.
PubMed 文献 · J Am Geriatr Soc · 2022-12-10

该回顾性队列研究纳入6821名≥65岁长期居住养老院的居民,比较格列美脲、格列吡嗪和格列本脲及初始剂量对严重低血糖、心衰、卒中和急性心梗的影响。格列美脲相比格列吡嗪严重低血糖风险更高,标准剂量相比减量风险更高,但心血管结局无差异。

要点

  • 格列美脲相比格列吡嗪严重低血糖风险更高(HR 1.6)。
  • 标准剂量相比减量严重低血糖风险更高(HR 2.2)。
  • 心血管结局在药物和剂量间无显著差异。

核心结论

  • 在长期居住养老院的居民中,新使用格列美脲和标准剂量磺脲类药物导致严重低血糖事件率更高。
  • 心血管结局可能不受磺脲类药物选择或剂量的影响。

研究设计与样本

  • 美国全国性回顾性队列研究,链接2008年1月至2010年9月Medicare理赔数据与MDS 2.0评估,纳入≥65岁长期居住养老院居民6821名。
  • 暴露为新起始的磺脲类药物(格列吡嗪、格列美脲、格列本脲)及剂量(标准或减量),随访1年。
  • 采用逆概率治疗加权和逆概率删失(死亡)加权,Cox回归模型估计风险比(HR)及稳健95%置信区间(CI)。

主要发现

  • 队列平均年龄81.4岁(标准差8.2),女性4816名(70.6%),白种非西班牙裔5164名(75.7%)。
  • 新使用格列吡嗪、格列美脲和格列本脲者严重低血糖事件率分别为30.3、49.0和35.9例/1000人年。
  • 格列美脲相比格列吡嗪严重低血糖HR 1.6(95% CI 1.0-2.4,p=0.04);格列本脲相比格列吡嗪HR 1.2(95% CI 0.7-1.9,p=0.59)。
  • 减量组和标准剂量组严重低血糖事件率分别为27.1和42.8例/1000人年(HR 2.2,95% CI 1.4-3.5,p<0.01)。
  • 心衰、卒中和急性心梗事件率在药物和剂量间相似。

临床怎么用

  • 在养老院老年居民中起始磺脲类药物时,优先选择低血糖风险较低的药物如格列吡嗪,并考虑使用减量。
  • 对使用格列美脲或标准剂量磺脲类药物的居民加强血糖监测,警惕严重低血糖事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The comparative safety of sulfonylureas (SUs) in nursing home (NH) residents remains understudied despite widespread use. We compared the effects of three SU medications and initial SU doses on adverse glycemic and cardiovascular events among NH residents. METHODS: This national retrospective cohort study linked Medicare claims with Minimum Data Set 2.0 assessments for long-stay NH residents aged ≥65 years between January 2008 and September 2010. Exposures were the SU medication initiated (glimepiride, glipizide, or glyburide) and doses (standard or reduced). One-year outcomes were hospitalizations or emergency department visits for severe hypoglycemia, heart failure (HF), stroke, and acute myocardial infarction (AMI). After the inverse probability of treatment and inverse probability of censoring by death weighting, we estimated hazard ratios (HR) using Cox regression models with robust 95% confidence intervals (CI). RESULTS: The cohort (N = 6821) included 3698 new glipizide, 1754 glimepiride, and 1369 glyburide users. Overall, the mean (standard deviation) age was 81.4 (8.2) years, 4816 (70.6%) were female, and 5164 (75.7%) were White non-Hispanic residents. The rates of severe hypoglycemia were 30.3 (95% CI 22.3-40.1), 49.0 (95% CI 34.5-67.5), and 35.9 (95% CI 22.2-54.9) events per 1000 person-years among new glipizide, glimepiride, and glyburide users, respectively (glimepiride versus glipizide HR 1.6, 95% CI 1.0-2.4, p = 0.04; glyburide versus glipizide HR 1.2, 95% CI 0.7-1.9, p = 0.59). The rates of severe hypoglycemia were 27.1 (95% CI 18.6-38.0) and 42.8 (95% CI 33.6-53.8) events per 1000 person-years among new users of reduced and standard SU doses, respectively (HR 2.2, 95% CI 1.4-3.5, p < 0.01). Rates of HF, stroke, and AMI were similar between medications and doses. CONCLUSIONS: Among long-stay NH residents, new use of glimepiride and standard SU doses resulted in higher rates of severe hypoglycemic events. Cardiovascular outcomes may not be affected by the choice of SU medication or dose.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Zullo AR, Riester MR, Hayes KN, et al. Comparative safety of sulfonylureas among U.S. nursing home residents. J Am Geriatr Soc. 2022. PMID: 36495141. doi:10.1111/jgs.18160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。